Flu vaccines pass €1 billion in Sanofi-Aventis's Q4
This article was originally published in Scrip
Sanofi-Aventis has reported a 10% increase in its fourth-quarter net income as sales of its influenza vaccines grew to almost €1.1 billion. The French firm's human vaccines business expanded by 65% in the quarter, pushing group net income to €1.8 billion. More to follow.
You may also be interested in...
Reports about delays to Moderna's Phase III plans adds to the biotech's rollercoaster ride, but its CEO insists it is still on track.
Currently serving at the WHO, Emer Cooke is set to return to EMA this month as executive director. The EMA’s management board has brought in new leadership to tackle challenges posed by Brexit, COVID-19 and recent agency restructuring.
A US bill aimed at promoting biosimilars by encouraging greater prescribing rates and creating a shared savings demonstration program for biosimilars has been warmly welcomed by the AAM.